Phase II Study of Peri-Operative Modified Folfirinox in Localized Pancreatic Cancer
Diseases and Conditions Researched
What is the purpose of this trial?
The primary objective of this study is to determine the progression free survival in patients with metastatic ;pancreatic ;cancer and in patients with locally advanced unresectable non-metastaticpancreatic ;cancer treated with a dose-attenuated modification of folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX). Secondary endpoints include: determine objective response rate according to RECIST; determine overall survival; evaluate toxicity; determine rate of resection in locally advanced unresectable stratum; correlate time to progression, objective response, and overall survival with early changes in glucose metabolism using [18F]-fluorodeoxyglucose (FDG)-positron emission tomography (PET) scanning.
Click here for detailed participation information for this trial.
|Sponsor:||Yale Cancer Center|
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.